drugset
drugset / Trial / NCT07584018

The DoHAICs Study Expansion Phase

NCT07584018 ↗

Phase 2 Not yet recruiting 90 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .

Timeline

Start
2026-05-20
Primary completion
2027-06-01
Completion
2027-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Donafenib Small molecule 200 mg Oral
Subject Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

hepatocellular carcinoma